ReviewFrontiers in medicine2021
T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses Between Infection and Vaccination: Challenges for Epidemiological Research.The Journal of infectious diseases · 2025Article
- Investigation of Long-Term CD4+ T Cell Receptor Repertoire Changes Following SARS-CoV-2 Infection in Patients with Different Severities of Disease.Diagnostics (Basel, Switzerland) · 2024Article
- Comparing population-level humoral and cellular immunity to SARS-Cov-2 in Bangalore, India.Scientific reports · 2024Article
- Article
- Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India.Scientific reports · 2024Article
- Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein.Frontiers in immunology · 2024Article
- Convalescent Adaptive Immunity Is Highly Heterogenous after SARS-CoV-2 Infection.Journal of clinical medicine · 2023Article
- COVID-19 vaccination exacerbates ex vivo IL-6 release from isolated PBMCs.Scientific reports · 2023Article
- The changing health impact of vaccines in the COVID-19 pandemic: A modeling study.Cell reports · 2023Article
- Architecture of the SARS-CoV-2-specific T cell repertoire.Frontiers in immunology · 2023Review
- Contribution of SARS-CoV-2 infection preceding COVID-19 mRNA vaccination to generation of cellular and humoral immune responses in children.Frontiers in immunology · 2023Article
- Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines.PLoS pathogens · 2022Article
- Article
- Article
- Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants.Biomedicines · 2022Article
- Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.Frontiers in immunology · 2022Article
- Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T cell responses are a key cornerstone to viral immunity to drive high-quality antibody responses, establishing memory for recall and for viral clearance. Inefficient recruitment of T cell responses plays a role in the development of severe COVID-19 and is also represented by reduced cellular responses in men, children, and diversity compared with other epitope-specific subsets and available T cell receptor diversity. SARS-CoV-2-specific T cell responses are elicited by multiple vaccine formats and augmented by prior infection for hybrid immunity. Epitope conservation is relatively well-maintained leading to T cell crossreactivity for variants of concern that have diminished serological responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.